Abstract
For the optimal performance of high throughput genomic technologies sufficient yields of high-quality DNA are crucial. Following microdissection, most samples fail to produce sufficient quantities of DNA for genome-wide experiments. Various PCR-based amplification methods have been used, but these usually produce nonuniform representations of the genome. Bacteriophage Phi29 DNA polymerase random-primed DNA amplification is based on isothermal multiple displacement amplification. We sought to define the genome representation of this method in a bacterial artificial chromosome microarray comparative genomic hybridisation (aCGH) platform. Test genomic female DNA was amplified using Phi29 amplification at four different starting concentrations (0.5, 5, 10 and 50 ng). These products were combined with unamplified and amplified genomic female DNA as reference. In addition, 50 ng of DNA from five microdissected breast cancer frozen samples, were amplified using the same method. Three combinations were performed: unamplified test with unamplified reference, amplified test with unamplified reference and both amplified tumour and reference DNA. aCGH was performed with an in-house 16 K BAC platform (a resolution of ∼100 Kb). Pearson's correlation tests and hierarchical clustering were performed to compare the profiles obtained. aCGH profiles obtained with amplified test and unamplified reference female genomic DNA showed copy number biases throughout the genome. These biases were more conspicuous with smaller amounts of starting material and mapped to regions of known copy number polymorphisms. When similar concentrations of test and reference DNA were amplified, the biases were significantly reduced, rendering accurate profiles. For the tumours, representative profiles were obtained when both test and reference DNA were amplified. Phi29 amplification induces copy number biases and unamplified material remains the gold standard for copy number analysis. For accurate results using Phi29 amplification, samples subjected to aCGH analysis should be combined with reference DNA amplified with the same method, using similar amounts of starting template.
Similar content being viewed by others
Main
Genome-wide techniques have played a major role in unravelling the molecular genetic pathways associated with tumorigenesis and tumour progression.1, 2 Comparative genomic hybridisation (CGH) was the first molecular method to allow a systematic analysis of chromosomal copy number changes throughout the entire genome.3 This method has been instrumental in the characterisation of the molecular genetic profiles of several types of human cancer.1, 4, 5, 6, 7 However, owing to the limited resolution of CGH, few tumour-suppressor genes or oncogenes have been identified using this technique. In recent years, microarray-based comparative genomic hybridisation (aCGH) has been devised to overcome the resolution limitation of CGH.1, 5, 6, 7
The potential of aCGH as a method to define the genomic profile of human tumours and to be used in the context of clinical outcome and treatment response prediction is enormous.1, 5, 6, 7 This is particularly important as targeted treatments for cancer patients based on specific genomic alterations (eg, HER2 amplification) are becoming clinically available. Unlike expression profiling analysis, where variable proportions of tumour and stromal components can be subjected to microarray experiments, aCGH requires a purity of >75% of neoplastic cells.8 With the advent of laser capture microdissection,9 it has become possible to study the genetic features of limited number of cells or small lesions. The limiting step for coupling laser capture microdissection or other microdissection methods with microarray CGH has been the amount of DNA retrieved with these methods. For the study of breast cancer this has become of paramount importance, given that most diagnosis are currently made on core needle biopsies, leaving very limited material for molecular analysis.
Whole-genome amplification (WGA) methods have been developed in order to obtain adequate DNA yields with the highest possible fidelity to the original profile.10, 11, 12, 13, 14 PCR-based amplification methods, including degenerate oligonucleotide primer polymerase chain reaction (DOP-PCR)10 and single-cell comparative genomic hybridisation (SCOMP),11 have been shown to provide a DNA yield sufficient for CGH analysis, however, some regions are reported to be preferentially amplified.12, 13 Awareness of these biases and improvements in CGH technology, including the use of standard reference intervals for CGH analysis,15, 16 has allowed the genetic study of amplified DNA. However, to reliably translate the increased resolution of microarray-based CGH into the identification of gene-specific copy number changes, unbiased amplification methods are required.
In this study, we sought to define the genome representation of Bacteriophage Phi29 DNA polymerase amplification in a high-density bacterial aCGH platform and to determine whether this method can be used to study the genome-wide profiles of microdissected samples.
Materials and methods
Samples and DNA Extraction
For the analysis of the accuracy of Phi29 in amplifying varying amounts of high-quality DNA, we used DNA extracted from peripheral blood lymphocytes of healthy female and male volunteers.
From 30 available breast cancer core biopsies, we selected five cases, where DNA extraction yielded >4 μg, for the comparison between the genetic profiles obtained with unamplified DNA and Phi29 amplified products. Fresh frozen sections of the tumours were stained with nuclear fast red and microdissected with a sterile needle (Terumo corporation®, Japan) under a stereomicroscope (Olympus SZ61®, Japan) to obtain a percentage of tumour cells in the remaining tissue greater than 75%.5 This study has been approved by The Royal Marsden Hospital Research Ethics Committee.
Genomic DNA was extracted using a standard proteinase K digestion followed by phenol/chlorophorm extraction and resuspended in TE buffer pH:7.5.5 The concentration of the samples was measured by spectophotometry (Ultrospec® 3100 pro, Amersham Bioscience, Amersham, UK).
Whole-Genome Amplification
GenomiPhi DNA amplification kit® was used following the manufacturer's instructions. Briefly, 1 μl of template was mixed with 9 μl of sample buffer. The mixture was denaturated at 95°C for 3 min and immediately cooled at 4°C for a minimum of 10 min. A combination of 9 μl of reaction buffer with 1 μl of the enzyme was added to the cooled sample and then incubated at 30°C for 16 h overnight. Inactivation of the enzyme was performed by heating the sample for 10 min at 65°C which was then cooled to 4°C. Postamplification cleanup was achieved by ethanol precipitation using the sodium acetate/EDTA (1.5 M sodium acetate pH>8 and 250 mM EDTA) buffer. Samples were resuspended in 22 μl of TE (pH: 7.5).
Quality Control PCR for Phi29 Amplification
Given that negative controls of Phi29 amplified reactions also show a smear in agarose gels, we determined whether the amplified products contained actual genomic sequences by performing a PCR,7 using primers specific for GAPDH and ER alpha genes: GAPDH (F: acagtccatgccatcactgc; R: gcttgacaaagtggtcgttg; 400 bp) and ER alpha gene (F: gggagaatgttgaaacacaag; R: ccagttgatcatgtgaaccag; 300 bp). A total reaction volume of 30 μl comprised 100 ng of genomic DNA, 1 × Taq buffer, 1.5 mM MgCl2, 0.2 mM dNTPs, and 0.133 μM of each forward and reverse primers and 1 U of Taq polymerase (Invitrogen, Paisley, UK). PCR reactions were performed in a Peltier thermal cycler (PTC-225) starting with 4 min at 94°C and 34 cycles (1 min at 94°C 1 min at 55°C and 3 min at 72°C, followed by 7 min at 72°C, ending at 15°C). Products were run in a 2% agarose gel electrophoresis with ethidium bromide staining.
Experimental Design
To determine whether Phi29 produces unbiased genome-wide amplification with different amounts of starting DNA, we used as reference either unamplified female genomic DNA or Phi29 amplified female genomic DNA at a concentration of 50 ng/μl. We then tested Phi29 amplified female genomic samples at concentrations of 0.5, 5, 10 and 50 ng/μl. We also performed experiments combining male genomic and female genomic DNA, in order to define the log2 ratios in the presence of a known 1:2 copy number ratio (ie, chromosome X in male vs female samples). For this purpose, we combined unamplified male genomic DNA with unamplified female genomic DNA, amplified male genomic DNA with unamplified female genomic DNA and both amplified DNA samples at the same starting concentration (50 ng/μl). Table 1 summarises the experiments we performed with male and female genomic DNA.
Following the findings from the experiments above, we combined female genomic DNA, both as test and reference, amplified using the same starting amount of DNA (0.5, 5, 10 ng).
We next tested whether the tumour DNA results obtained with Phi29 were accurate and representative, using the profiles obtained with unamplified DNA as the ‘gold standard’. Each tumour was subjected to three separate analyses (Table 2): unamplified tumour DNA with unamplified reference (pooled healthy female genomic) DNA, Phi29 amplified tumour DNA with unamplified reference DNA, and Phi29 amplified tumour and reference DNA.
To study the genomic regions (comprising 3 or more consecutive BACs) consistently harbouring genomic gains or losses due to amplification bias, we selected the experiments where amplified healthy female genomic DNA was combined with unamplified healthy female genomic DNA as reference. Those regions that were consistently gained or lost in >2 experiments were considered as recurrent biases. These regions were subsequently mapped to define their GC content and we investigated whether they preferentially mapped to regions of known copy number polymorphisms. A frequency plot was generated to illustrate each BAC showing Phi29 amplification-induced bias in >2 experiments (Figure 5).
Microarray CGH
The aCGH platform used for this study was constructed in the Breakthrough Breast Cancer Research Centre and comprises ∼16 000 clones, spaced at approximately 100 kb throughout the genome and spotted onto Corning GAPSII-coated glass slides (Corning, NY, USA). Labelling, hybridisation and washes were carried out essentially as previously described.5, 17, 18 Briefly, 400 ng of test and reference genomic DNA were labelled with Cy3-dCTP or Cy5-dCTP (Amersham Bioscience, Amersham, UK) using a Bioprime labelling kit (Invitrogen, Paisley, UK) according to the manufacturers protocol modified to incorporate 0.6 mM dCTP, and 1.2 mM dATP, dGTP and dTTP. The unincorporated nucleotides were removed with MinElute purification columns (Qiagen Ltd, West Sussex, UK). All experiments were performed in duplicate (‘dye swaps’) to minimise dye-biases.
Image Acquisition and Data Analysis
Slides were scanned using an Axon 4000B scanner (Axon Instruments, Burlingame, CA, USA) and images were processed using Genepix Pro 3.0 image analysis software (Axon Instruments). The log2 ratios were normalised for spatial and intensity-dependent biases using a two-dimensional loess regression and then averaged across the ‘dye-swaps’. This left a final data set of 13 263 clones with unambiguous mapping information according to the March 2006 build of the human genome (hg17). Data were smoothed using a local polynomial adaptive weights smoothing (aws) procedure for regression problems with additive errors.5, 17 Thresholds for defining genomic gains and losses were obtained using data from unamplified female vs female and female vs male genomic DNA, as previously described.5, 18 A categorical analysis was applied to each clone on the array after classification as gain, loss or no-change according to their smoothed log2 ratio values. Smoothed log2 ratio values <–0.182 were categorized as losses, those >0.182 as gains, and those in between as unchanged. Pearson's correlation test was used to compare the profiles obtained with amplified and unamplified experiments performed for the same tumour. Identical hybridisations of amplified material (test and reference) from two of the tumour samples were subjected to array CGH on different days on different batches of array CGH slides and used as a control for an accurate interpretation of Pearson's correlations results. Unsupervised clustering was performed on smoothed and ‘thresholded’ data using Ward's method based on Euclidean distance. Data processing and analysis was carried out in R 2.0.1 (http://www.r-project.org/) and BioConductor 1.5 (http://www.bioconductor.org/), making extensive use of modified versions of the packages aCGH, marray and aws in particular.
Results
DNA Extraction, Amplification and PCR Quality Control
All tumour samples had greater than 75% invasive component after microdissection. The DNA extraction yielded total products of around 1.4–9 μg (median=3.25 μg), with an OD260/280 ratio >1.8.
Amplification of genomic female DNA with 0.5, 5, 10 and 50 ng yielded equivalent amounts of final product for all amplifications ranging from 4.3 to 6.4 μg (median=5.35 μg; 100- to 10 000-fold amplification), suggesting that fold amplification was inversely correlated with the starting amount of DNA.
Amplification of the tumour samples was carried out from a starting concentration of 50 ng. GenomiPhi® provided a 90- to 108-fold amplification, with the amount of DNA obtained ranging from 4.4 to 5.4 μg (median=4.85 μg). Gene-specific PCR for amplified genomic DNA and tumour samples yielded products of the expected sizes (400 bp length), whereas products obtained in the negative controls failed to show specific bands, rather a smear was observed (Supplementary Figure 1).
Assessment of Fidelity of Phi29 WGA
The profiles obtained with Phi29 amplified female genomic DNA samples varied according to the starting DNA concentration and the use of amplified reference and test DNA. Analysis of the molecular genetic profiles obtained with starting amounts of 0.5 and 5 ng DNA revealed significant biases induced by Phi29 amplification, when combined with unamplified reference (Table 3, Figure 1a, d, g, j and m). When amplified test samples were hybridised with a standard amplified reference (50 ng), a significant stepwise decrease in the percentage of BACs showing either gains or losses was observed with increasing amounts of starting material (Table 3, Figure 1b, e, h, k and n). The bias was completely cancelled out when combining both test and reference amplified from 50 ng (Figure 1k). In all experiments, these biases were more conspicuous in the comparisons carried out using nonamplified reference DNA compared to those with amplified reference from 50 ng of DNA.
Given that the Phi29 amplification bias was completely cancelled out in the experiment using independent reactions with 50 ng of test and reference starting material (Table 3, Figure 1k), we next tested how the bias would be affected when matched starting amounts of DNA were used for both reference and test. We observed that <0.5% of the BACs showed Phi29 amplification-induced copy number biases when products from separate reactions with the same starting amount were combined (Table 3, Figure 1c, f, i, k and n). Optimal results when using amplified material were obtained in the experiments where both test and reference were amplified using the same amount of starting DNA (Figure 1c, f, i, k and n).
We then performed hierarchical cluster analysis for all combinations of genomic DNA experiments and found that unamplified test and reference samples segregated together with those carried out with both amplified test and reference DNA using the same starting amount of DNA (Figure 2).
Breast Tumours
Based upon the results obtained with female genomic DNA, the starting concentration for all tumour samples before amplification was 50 ng/μl. In all cases, the combination of both amplified test and reference had a higher Pearson's correlation value (r2) than the combination of amplified with unamplified material. When profiles obtained with unamplified DNA were compared with those obtained with amplified test and reference, we found a very good correlation in two tumours (r2>0.8) (Figure 3), good correlation in two cases (r2>0.7) and moderate correlation for the last case (r2=0.5) (M67A). The correlation for the control experiments performed in different days was in both cases r2≥0.9. We then performed hierarchical clustering with all experiments. As expected, all experiments from those tumours with good-to-very good correlation scores segregated together (Figure 4).
Assessment of the Phi29-Induced Genomic Bias
To define the regions with recurrent copy number biases, experiments combining amplified female genomic DNA and unamplified female genomic reference DNA were used. Applying the thresholds of 0.182 (‘gains’) and −0.182 (‘losses’), recurrent increases in copy number due to amplification bias (‘gains’) were more frequent than decreases in copy number (‘losses’). We found 62 regions of consistent gain and 10 regions of loss (Figure 5 and Supplementary Table 1).
We then investigated whether regions of amplification bias mapped to genomic regions with known copy number variations (CNVs) (http://projects.tcag.ca/variation/). Thirty-eight out of the 62 regions of ‘gains’ (60%) mapped to known CNV regions. Eighty per cent of ‘losses’ consistently mapped to previously described CNV. These regions of misrepresentation were found to be GC-rich, with a mean GC of 45.6% (s.d.=22.8, median=45.46%).
Discussion
Bacteriophage Phi29 DNA polymerase amplification is based on an isothermal reaction that uses random hexamer primers to anneal to the genomic template at multiple sites to initiate replication.19, 20 This isothermal technique is reported to have several advantages when compared to PCR-based methods, including the linear amplification of the DNA and the proofreading property of the enzyme, which leads to an increased accuracy and therefore, guarantees higher fidelity of the process.21 As synthesis proceeds, strand displacement of complementary DNA generates new single-stranded DNA available to be primed by additional primers. Although the Phi29 WGA clearly results in recurrent genomic misrepresentations, this technique is reported to have a threefold error rate for over-/under representation, which is significantly lower than the 1000-fold reported for PCR-based WGA methods.20 Moreover, Phi29 WGA has been successfully applied to SNP and sequencing studies.22, 23 On the other hand, a previous microarray CGH study demonstrated that Phi29 induces representational distortion, likely to be resultant from variability in priming density and processing of repetitive and polymorphic sequences.24
In our hands, Phi29 amplification provided 90 (for 50 ng)—10 000 (for 0.5 ng) fold amplification, depending on the amount of starting template. Given the higher fold amplification with lower amounts of starting material, the highest amplification levels and proportionally highest yields were obtained with the lowest starting amount of material (ie, 0.5 ng). However, our study demonstrates that Phi29 amplification induces misrepresentation of several regions, showing artefactual ‘gains’ and ‘losses’ on the array CGH profiles and that these amplification biases are more frequent when low amounts (0.5–10 ng) of starting template are used, suggesting that the bias is more conspicuous in reactions with higher fold amplification.
Our findings provide evidence to suggest that Phi29 copy number change biases are not random (ie, map to specific genomic regions) and depend on the starting amount of template DNA, given that these are corrected (ie, <0.5% of genomic biases) when both test and reference DNA are amplified using the same amount of starting material. Mutation analysis and single-nucleotide polymorphism studies have also demonstrated that Phi29-induced copy number changes are nonrandom and can be effectively corrected using amplified reference DNA.22, 25, 26 Given that the bias is dependent on the starting amount of DNA and does not affect all loci in every sample, the statistical methods proposed by Cardoso et al24 to circumvent this problem, may be effective in some but not all scenarios. However, our results support the use of amplified reference22, 25, 26 to compensate for these areas of regional misrepresentation in order to obtain accurate results.
The high-resolution of the aCGH platform used in the present study allowed for an accurate mapping of the regions with Phi29 copy number biases. Using DNA from the same pooled healthy female source amplified in separate reactions, we have observed that a high percentage of these false ‘gains’ and ‘losses’ map to known CNVs.27, 28, 29 In addition, several loci of bias that did not correspond to known CNVs, mapped either to flanking regions of CNVs or telomeric (eg, 5q35, 17q25) and pericentromeric areas (eg, 11q13.1, 16p11) (Figure 5). In previous reports, regions of recurrent amplification bias have been located in areas of highly repetitive elements,22, 25, 26 however, this is the first time that these biases have been shown to map to known CNVs in the human genome. Although the underlying mechanism of this preferential amplification of specific areas by Phi29 polymerase remains unclear, it appears to be related with the fold amplification rates and to the amount of starting material.
Bredel et al25 have observed a correlation between the GC content and the biases (underepresentation) induced by Phi29 amplification. This enrichment in the GC content had been shown to affect the efficiency of polymerase reaction amplification.30 In our study, the regions of misrepresentation also showed enrichment for GC repeats (average of 45.6%), which is slightly higher than that of whole-genome (41%) GC content.
In conclusion, although Phi29 amplification provides efficient WGA, this method still induces copy number biases on BAC aCGH analysis, which can be reduced with increased amounts of starting material and almost completely cancelled out by using amplified test and reference DNA from the similar starting amounts of template. However, unamplified material rendered the best results and should still be considered the ‘gold standard’ for molecular genetic profiling with microarray-based comparative genomic hybridisation.
References
Albertson DG, Collins C, McCormick F, et al. Chromosome aberrations in solid tumors. Nat Genet 2003;34:369–376.
Weber BL . Cancer genomics. Cancer Cell 2002;1:37–47.
Kallioniemi A, Kallioniemi OP, Sudar D, et al. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 1992;258:818–821.
Tirkkonen M, Tanner M, Karhu R, et al. Molecular cytogenetics of primary breast cancer by CGH. Genes Chromosomes Cancer 1998;21:177–184.
Reis-Filho JS, Simpson PT, Jones C, et al. Pleomorphic lobular carcinoma of the breast: role of comprehensive molecular pathology in characterization of an entity. J Pathol 2005;207:1–13.
Albertson DG, Pinkel D . Genomic microarrays in human genetic disease and cancer. Hum Mol Genet 2003;12 (Spec no 2):R145–R152.
van Beers EH, Joosse SA, Ligtenberg MJ, et al. A multiplex PCR predictor for aCGH success of FFPE samples. Br J Cancer 2006;94:333–337.
Weiss MM, Hermsen MA, Meijer GA, et al. Comparative genomic hybridisation. Mol Pathol 1999;52:243–251.
Bonner RF, Emmert-Buck M, Cole K, et al. Laser capture microdissection: molecular analysis of tissue. Science 1997;278:1481, 3.
Little SE, Vuononvirta R, Reis-Filho JS, et al. Array CGH using whole genome amplification of fresh-frozen and formalin-fixed, paraffin-embedded tumor DNA. Genomics 2006;87:298–306.
Stoecklein NH, Erbersdobler A, Schmidt-Kittler O, et al. SCOMP is superior to degenerated oligonucleotide primed-polymerase chain reaction for global amplification of minute amounts of DNA from microdissected archival tissue samples. Am J Pathol 2002;161:43–51.
Cheung VG, Nelson SF . Whole genome amplification using a degenerate oligonucleotide primer allows hundreds of genotypes to be performed on less than one nanogram of genomic DNA. Proc Natl Acad Sci USA 1996;93:14676–14679.
Telenius H, Carter NP, Bebb CE, et al. Degenerate oligonucleotide-primed PCR: general amplification of target DNA by a single degenerate primer. Genomics 1992;13:718–725.
Obermann EC, Junker K, Stoehr R, et al. Frequent genetic alterations in flat urothelial hyperplasias and concomitant papillary bladder cancer as detected by CGH, LOH, and FISH analyses. J Pathol 2003;199:50–57.
Kirchhoff M, Gerdes T, Rose H, et al. Detection of chromosomal gains and losses in comparative genomic hybridization analysis based on standard reference intervals. Cytometry 1998;31:163–173.
Kirchhoff M, Gerdes T, Maahr J, et al. Automatic correction of the interfering effect of unsuppressed interspersed repetitive sequences in comparative genomic hybridization analysis. Cytometry 1997;28:130–134.
Natrajan R, Williams RD, Hing SN, et al. Array CGH profiling of favourable histology Wilms tumours reveals novel gains and losses associated with relapse. J Pathol 2006;210:49–58.
Reis-Filho J, Pinheiro C, Lambros M, et al. EGFR amplification and lack of activating mutations in metaplastic breast carcinomas. J Pathol 2006;209:445–453.
Blanco L, Bernad A, Lazaro JM, et al. Highly efficient DNA synthesis by the phage phi 29 DNA polymerase. Symmetrical mode of DNA replication. J Biol Chem 1989;264:8935–8940.
Dean FB, Hosono S, Fang L, et al. Comprehensive human genome amplification using multiple displacement amplification. Proc Natl Acad Sci USA 2002;99:5261–5266.
Esteban JA, Salas M, Blanco L . Fidelity of phi 29 DNA polymerase. Comparison between protein-primed initiation and DNA polymerization. J Biol Chem 1993;268:2719–2726.
Paez JG, Lin M, Beroukhim R, et al. Genome coverage and sequence fidelity of phi29 polymerase-based multiple strand displacement whole genome amplification. Nucleic Acids Res 2004;32:e71.
Rook MS, Delach SM, Deyneko G, et al. Whole genome amplification of DNA from laser capture-microdissected tissue for high-throughput single nucleotide polymorphism and short tandem repeat genotyping. Am J Pathol 2004;164:23–33.
Cardoso J, Molenaar L, de Menezes RX, et al. Genomic profiling by DNA amplification of laser capture microdissected tissues and array CGH. Nucleic Acids Res 2004;32:e146.
Bredel M, Bredel C, Juric D, et al. Amplification of whole tumor genomes and gene-by-gene mapping of genomic aberrations from limited sources of fresh-frozen and paraffin-embedded DNA. J Mol Diagn 2005;7:171–182.
Lage JM, Leamon JH, Pejovic T, et al. Whole genome analysis of genetic alterations in small DNA samples using hyperbranched strand displacement amplification and array-CGH. Genome Res 2003;13:294–307.
Freeman JL, Perry GH, Feuk L, et al. Copy number variation: new insights in genome diversity. Genome Res 2006;16:949–961.
Iafrate AJ, Feuk L, Rivera MN, et al. Detection of large-scale variation in the human genome. Nat Genet 2004;36:949–951.
Sharp AJ, Locke DP, McGrath SD, et al. Segmental duplications and copy-number variation in the human genome. Am J Hum Genet 2005;77:78–88.
Arezi B, Xing W, Sorge JA, et al. Amplification efficiency of thermostable DNA polymerases. Anal Biochem 2003;321:226–235.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Laboratory Investigation website (http://www.nature.com/labinvest)
Rights and permissions
About this article
Cite this article
Arriola, E., Lambros, M., Jones, C. et al. Evaluation of Phi29-based whole-genome amplification for microarray-based comparative genomic hybridisation. Lab Invest 87, 75–83 (2007). https://doi.org/10.1038/labinvest.3700495
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/labinvest.3700495
Keywords
This article is cited by
-
Impact of template denaturation prior to whole genome amplification on gene detection in high GC-content species, Burkholderia mallei and B. pseudomallei
BMC Research Notes (2024)
-
Evaluation of bias induced by viral enrichment and random amplification protocols in metagenomic surveys of saliva DNA viruses
Microbiome (2018)
-
Number of blastocysts biopsied as a predictive indicator to obtain at least one normal/balanced embryo following preimplantation genetic diagnosis with single nucleotide polymorphism microarray in translocation cases
Journal of Assisted Reproduction and Genetics (2017)
-
Whole-genome-amplified DNA as a source for mutational analysis underestimates the frequency of mutations in pediatric acute myeloid leukemia
Leukemia (2013)